235 related articles for article (PubMed ID: 21468463)
1. Hormone receptors and HER-2 status as surrogates for breast cancer molecular subtypes prognosticate for disease control in node negative Asian patients treated with breast conservation therapy.
Wong FY; Chin FK; Lee KA; Soong YL; Chua ET
Ann Acad Med Singap; 2011 Feb; 40(2):90-6. PubMed ID: 21468463
[TBL] [Abstract][Full Text] [Related]
2. [Clinical characteristics and survival in the operable breast cancer patients with different molecular subtypes].
Zhang HM; Zhang BN; Xuan LX; Zhao P
Zhonghua Zhong Liu Za Zhi; 2009 Jun; 31(6):447-51. PubMed ID: 19950556
[TBL] [Abstract][Full Text] [Related]
3. Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associated with local and distant recurrence after breast-conserving therapy.
Nguyen PL; Taghian AG; Katz MS; Niemierko A; Abi Raad RF; Boon WL; Bellon JR; Wong JS; Smith BL; Harris JR
J Clin Oncol; 2008 May; 26(14):2373-8. PubMed ID: 18413639
[TBL] [Abstract][Full Text] [Related]
4. Basal subtype of invasive breast cancer is associated with a higher risk of true recurrence after conventional breast-conserving therapy.
Hattangadi-Gluth JA; Wo JY; Nguyen PL; Abi Raad RF; Sreedhara M; Niemierko A; Freer PE; Georgian-Smith D; Bellon JR; Wong JS; Smith BL; Harris JR; Taghian AG
Int J Radiat Oncol Biol Phys; 2012 Mar; 82(3):1185-91. PubMed ID: 21601377
[TBL] [Abstract][Full Text] [Related]
5. [Clinical features and prognosis analysis of different breast cancer molecular subtypes].
Yang Q; Chen J; Li HJ; Yu M; Tian CX; Lü Q
Zhonghua Zhong Liu Za Zhi; 2011 Jan; 33(1):42-6. PubMed ID: 21575463
[TBL] [Abstract][Full Text] [Related]
6. Molecular breast cancer subtypes in premenopausal and postmenopausal African-American women: age-specific prevalence and survival.
Ihemelandu CU; Leffall LD; Dewitty RL; Naab TJ; Mezghebe HM; Makambi KH; Adams-Campbell L; Frederick WA
J Surg Res; 2007 Nov; 143(1):109-18. PubMed ID: 17950079
[TBL] [Abstract][Full Text] [Related]
7. The association between biological subtype and locoregional recurrence in newly diagnosed breast cancer.
Gabos Z; Thoms J; Ghosh S; Hanson J; Deschênes J; Sabri S; Abdulkarim B
Breast Cancer Res Treat; 2010 Nov; 124(1):187-94. PubMed ID: 20814819
[TBL] [Abstract][Full Text] [Related]
8. Long-Term Outcomes of Immunohistochemically Defined Subtypes of Breast Cancer Less Than or Equal to 2 cm After Breast-Conserving Surgery.
Pata G; Guaineri A; Bianchi A; Amoroso V; Pasinetti N; Pasini M
J Surg Res; 2019 Apr; 236():288-299. PubMed ID: 30694768
[TBL] [Abstract][Full Text] [Related]
9. Differential impact of hormone receptor status on survival and recurrence for HER2 receptor-positive breast cancers treated with Trastuzumab.
McGuire A; Kalinina O; Holian E; Curran C; Malone CA; McLaughlin R; Lowery A; Brown JAL; Kerin MJ
Breast Cancer Res Treat; 2017 Jul; 164(1):221-229. PubMed ID: 28378298
[TBL] [Abstract][Full Text] [Related]
10. [Clinical characteristics and prognosis of different subtypes of breast cancer].
Yuan ZY; Wang SS; Zhu MQ; Zheng L; Luo WB; Zhou ZM; Guan ZZ
Zhonghua Zhong Liu Za Zhi; 2008 Jun; 30(6):456-61. PubMed ID: 19024523
[TBL] [Abstract][Full Text] [Related]
11. [Prognostic value of estrogen receptor, progesterone receptor and human epidermal growth factor receptor-2 in node positive breast cancer patients treated by mastectomy].
Wang SL; Li YX; Song YW; Wang WH; Jin J; Liu YP; Liu XF; Yu ZH
Zhonghua Zhong Liu Za Zhi; 2010 Jul; 32(7):520-5. PubMed ID: 21029696
[TBL] [Abstract][Full Text] [Related]
12. Molecular class as a predictor of locoregional and distant recurrence in the neoadjuvant setting for breast cancer.
Vargo JA; Beriwal S; Ahrendt GM; Soran A; Johnson RR; McGuire K; Bhargava R
Oncology; 2011; 80(5-6):341-9. PubMed ID: 21791944
[TBL] [Abstract][Full Text] [Related]
13. Is biological subtype prognostic of locoregional recurrence risk in women with pT1-2N0 breast cancer treated with mastectomy?
Truong PT; Sadek BT; Lesperance MF; Alexander CS; Shenouda M; Raad RA; Taghian AG
Int J Radiat Oncol Biol Phys; 2014 Jan; 88(1):57-64. PubMed ID: 24161421
[TBL] [Abstract][Full Text] [Related]
14. Histological grade provides significant prognostic information in addition to breast cancer subtypes defined according to St Gallen 2013.
Ehinger A; Malmström P; Bendahl PO; Elston CW; Falck AK; Forsare C; Grabau D; Rydén L; Stål O; Fernö M;
Acta Oncol; 2017 Jan; 56(1):68-74. PubMed ID: 27762648
[TBL] [Abstract][Full Text] [Related]
15. Prediction of local recurrence, distant metastases, and death after breast-conserving therapy in early-stage invasive breast cancer using a five-biomarker panel.
Millar EK; Graham PH; O'Toole SA; McNeil CM; Browne L; Morey AL; Eggleton S; Beretov J; Theocharous C; Capp A; Nasser E; Kearsley JH; Delaney G; Papadatos G; Fox C; Sutherland RL
J Clin Oncol; 2009 Oct; 27(28):4701-8. PubMed ID: 19720911
[TBL] [Abstract][Full Text] [Related]
16. Pathological features and prognosis of different molecular subtypes of breast cancer.
Wang GS; Zhu H; Bi SJ
Mol Med Rep; 2012 Oct; 6(4):779-82. PubMed ID: 22797840
[TBL] [Abstract][Full Text] [Related]
17. Effect of dose-dense adjuvant chemotherapy in hormone receptor positive/HER2-negative early breast cancer patients according to immunohistochemically defined luminal subtype: an exploratory analysis of the GIM2 trial.
Conte B; Bruzzone M; Lambertini M; Poggio F; Bighin C; Blondeaux E; De Laurentiis M; Valle E; Cognetti F; Nisticò C; De Placido S; Garrone O; Gamucci T; Montemurro F; Puglisi F; Cardinali B; Fregatti P; Miglietta L; Boccardo F; Ceppi M; Del Mastro L;
Eur J Cancer; 2020 Sep; 136():43-51. PubMed ID: 32634760
[TBL] [Abstract][Full Text] [Related]
18. Clinical features and survival analysis of different subtypes of patients with breast cancer brain metastases.
Bai B; Yuan ZY; Liu DG; Teng XY; Wang SS
Chin J Cancer; 2010 Apr; 29(4):413-9. PubMed ID: 20346218
[TBL] [Abstract][Full Text] [Related]
19. Breast-Conserving Therapy Versus Mastectomy in Young Breast Cancer Patients Concerning Molecular Subtypes: A SEER Population-Based Study.
Yu P; Tang H; Zou Y; Liu P; Tian W; Zhang K; Xie X; Ye F
Cancer Control; 2020; 27(1):1073274820976667. PubMed ID: 33356518
[TBL] [Abstract][Full Text] [Related]
20. Estrogen receptor, progesterone receptor, HER-2, and response to postmastectomy radiotherapy in high-risk breast cancer: the Danish Breast Cancer Cooperative Group.
Kyndi M; Sørensen FB; Knudsen H; Overgaard M; Nielsen HM; Overgaard J;
J Clin Oncol; 2008 Mar; 26(9):1419-26. PubMed ID: 18285604
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]